Ablukast

阿布鲁司特

Ablukast

A656352-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction. Ablukast is LTD4 receptor antagonist . In Vitro Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female BALB/c miceDosage: Concentrations of 0.1 , 0.5 , 1.0 and 5.0 % of Ablukast Administration: Applied to one of the pretreated ears 1 h after elicitation and at 24 h intervals on the following 4 days; three times daily Result: Effectively reduced DNFB-induced ear swelling.

阿鲁司特（Ro 23-3544）是一种特异性和活性白三烯受体拮抗剂。阿鲁司特能有效减轻 LTC4 和抗原诱导的支气管收缩。Ablukast 是 LTD4 受体拮抗剂。

96566-25-5(DMSO)

C28H34O8

498.56 g/mol

O=C(O)C1CCC2=CC(C(C)=O)=C(C=C2O1)OCCCCCOC3=CC=C(C(O)=C3CCC)C(C)=O